WHO ICTRP trial
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY…
NL-OMON55386 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55386 |
|---|---|
| Public title | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS |
| Scientific title | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN SUBJECTS WITH ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS - AS0010 235075 |
| Primary sponsor | UCB Biopharma SRL |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States of America |
| Conditions | Non-Radiographic Axial Spondyloarthritis - Bechterew's disease;10003816;Non-Radiographic Axial Spondyloarthritis - Bechterew's disease |
| Interventions | Treatment(s), dose(s), mode of administration, and duration: Bimekizumab or placebo will be administered sc by unblinded study personnel at the study site. Suitable areas for sc injections are the lateral abdominal wall, upper arm, and… |
| Registration date | Apr 20, 2021 |
| Target size | 6 |
| Secondary IDs | 2017-003064-13;NL69336.028.19;NTC03928704 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: